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Background: Germline mutations within DNA-repair genes are implicated in susceptibility to multiple forms of cancer. For
prostate cancer (PrCa), rare mutations in BRCA2 and BRCA1 give rise to moderately elevated risk, whereas two ofB100 common,
low-penetrance PrCa susceptibility variants identified so far by genome-wide association studies implicate RAD51B and RAD23B.
Methods: Genotype data from the iCOGS array were imputed to the 1000 genomes phase 3 reference panel for 21 780 PrCa cases
and 21 727 controls from the Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the Genome
(PRACTICAL) consortium. We subsequently performed single variant, gene and pathway-level analyses using 81 303 SNPs within
20 Kb of a panel of 179 DNA-repair genes.
Results: Single SNP analyses identified only the previously reported association with RAD51B. Gene-level analyses using the SKAT-C
test from the SNP-set (Sequence) Kernel Association Test (SKAT) identified a significant association with PrCa for MSH5. Pathway-
level analyses suggested a possible role for the translesion synthesis pathway in PrCa risk and Homologous recombination/Fanconi
Anaemia pathway for PrCa aggressiveness, even though after adjustment for multiple testing these did not remain significant.
Conclusions: MSH5 is a novel candidate gene warranting additional follow-up as a prospective PrCa-risk locus. MSH5 has
previously been reported as a pleiotropic susceptibility locus for lung, colorectal and serous ovarian cancers.
Prostate Cancer (PrCa) is the most frequently diagnosed cancer
among men in developed countries and despite high survival rates
also one of the highest for mortality (Cancer Research UK, 2014;
Quaresma et al, 2015). However, as the majority of prostate
neoplasms develop extremely slowly, many do not require clinical
intervention, which coupled with the low specificity of the
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prostate-specific antigen test for clinically relevant forms of the
disease could potentially lead to considerable over-diagnosis and
overtreatment of patients for relatively modest reductions in
mortality (Ilic et al, 2013). In conjunction with the establishment of
improved biomarkers for lethal PrCa, the identification of
individuals at greater risk of developing prostate tumours that
require clinical intervention would also help inform more targeted
and appropriate application of treatment. The heritability of PrCa
is believed to be the highest of all the common forms of cancer
(Hjelmborg et al, 2014). This is consistent with observations from
genome-wide association studies (GWAS), which have to date
identified 4100 low-penetrance susceptibility variants for PrCa,
two of which implicate the DNA-repair genes RAD51B and
RAD23B (Xu et al, 2012; Al Olama et al, 2014; Eeles et al, 2014;
Amin Al Olama et al, 2015). In addition, rare germline mutations
in a small number of genes have been reported, with varying
degrees of evidence, as potentially conferring greater risks of PrCa,
including the DNA-repair genes ATM, BRCA1, BRCA2, BRIP1,
CHEK2 and NBN (Dong et al, 2003; Kote-Jarai et al, 2009, 2011;
Leongamornlert et al, 2012, 2014; Robinson et al, 2015). Recently,
increasing evidence has demonstrated that these germline DNA-
repair gene mutation carriers are at increased likelihood of
experiencing advanced disease, metastatic spread and poorer
survival outcome; yet these mutations also hold promise as
potentially clinically actionable and responsive to targeted treat-
ments (Castro et al, 2013; Cybulski et al, 2013; Leongamornlert
et al, 2014; Robinson et al, 2015). In spite of these discoveries, the
majority of the excess familial risk of PrCa still remains to be
explained (Attard et al, 2015), with the contribution of DNA-repair
gene variants identified to date making them attractive candidates
for further investigation. In this study, using data from the iCOGS
project imputed to the 1000 Genomes Phase 3 reference panel, we
have analysed a large panel of DNA-repair gene variants for 21 780
PrCa cases and 21 727 controls of European ancestry from the
Prostate Cancer Association Group to Investigate Cancer Asso-
ciated Alterations in the Genome (PRACTICAL) Consortium
(Eeles et al, 2013). Analyses were performed at single variant, gene
and pathway levels to maximise the power to detect putative
associations with lower frequency variants or those with modest
effect sizes.
MATERIALS AND METHODS
Samples. Samples for the iCOGS study were drawn from
25 studies participating in the PRACTICAL Consortium. The
majority of studies were population-based or hospital-based
case–control studies, or nested case–control studies; some studies
selected samples by age or oversampled for cases with a family
history of prostate cancer. Further information regarding the
samples from the PRACTICAL Consortium included on
the iCOGS array may be found within the original publication
(Eeles et al, 2013). Analyses for DNA-repair gene variants were
restricted to samples of European ancestry. In total, genotype data
for 21 780 PrCa cases and 21 727 matched controls were available
after quality control.
Genotyping and imputation. Genotyping was performed as part
of the iCOGS project. This utilised a custom genotyping array
designed in collaboration between the PRACTICAL, BCAC (Breast
Cancer Association Consortium), OCAC (Ovarian Cancer Asso-
ciation Consortium) and CIMBA (Consortium of Investigators of
Modifiers of BRCA1/2) consortia. Detailed information about the
design, genotyping and quality control procedures for iCOGS can
be found within the original publication (Eeles et al, 2013). In total
211 155 SNPs were genotyped on the iCOGS array, of which 3510
were situated within our defined DNA-repair gene regions.
Imputation of the iCOGS PRACTICAL data was performed based
on sequence data for 2504 samples from the 1000 Genomes
phase 3 reference panel (IMPUTE2 haplotype panel, October
2014 release; https://mathgen.stats.ox.ac.uk/impute/1000GP%20
Phase%203%20haplotypes%206%20October%202014.html) using
SHAPEIT (v2 r778) and IMPUTE v2.3.1 in 588 chunks with a
median size of 5Mb (Howie et al, 2009; Delaneau et al, 2013).
Imputed data for variants with INFO scores X0.3 and
MAF 40.001 were included in these analyses, which retained
a total of 81 303 variants within the studied DNA-repair
gene regions.
Gene/region selection. We identified a total of 179 genes with
a core function in DNA-damage repair from the literature
that intersected imputed iCOGS genotype data. We annotated
DNA-repair genes to a single primary DNA-repair pathway
according to previous curations (Wood et al, 2005; Kang et al,
2012). The genes analysed in this study represent the pathways
Homologous recombination/Fanconi Anaemia signalling net-
work (HR/FA), base excision repair (BER), non-homologous end
joining (NHEJ), mismatch repair (MMR), nucleotide excision
repair (NER), translesion synthesis (TLS), ATM signalling
(ATM), RECQ helicase family (RECQ), cross-link repair
(XLR), and other miscellaneous DNA-repair genes with func-
tions including endonuclease/exonuclease activity and modifica-
tion of chromatin structure (Other). Gene coordinates were
assigned according to GENCODE release 19 (GRCh37.p13),
with a 20-kb flank added to define the study region for each gene,
in order to focus primarily on capturing gene and promoter
centric variation over that within regulatory elements, which can
be located at variable and potentially relatively large distances
from the gene itself. Variants were annotated using wANNO-
VAR to facilitate designation as coding, intronic, UTR,
splice and intergenic (Wang et al, 2010; Chang and Wang,
2012). A full list of the DNA-repair genes analysed in this study,
their pathway annotations, region coordinates and the number
of typed and imputed variants available is included in
Supplementary Table 1.
Statistical analyses. Analyses were adjusted for study groups
and the first eight principal components. For single-SNP
analyses the genome-wide significance threshold was employed
(Po5 10 8), whereas for gene and pathway level tests the
Bonferroni correction was used to determine multiple testing
adjusted significance thresholds (gene Po2.7 10 4, pathway
Po5.56 10 3).
All analyses were carried out using R. For single-SNP analyses,
per allele odds ratios were estimated using logistic regression.
SKAT tests were performed using the SKAT package for R (http://
CRAN.R-project.org/package=SKAT). We used the SKAT-O and
SKAT-C tests for optimal analyses of the combined effect of
multiple rare variants and common and rare variants, respectively
(Wu et al, 2011; Lee et al, 2012; Ionita-Laza et al, 2013). Tests were
conducted using default parameters and a common/rare cutoff
threshold of MAF¼ 0.01 for the SKAT-C test. StepAIC and SKAT
leave one out were used to further interrogate the significant SKAT
signal at the MSH5 gene for the individual variants that best
described the signal.
Analyses for low-grade vs high-grade PrCa were carried out
based on two clinical criteria. For stringent comparison of non-
aggressive and aggressive PrCa, we defined NCCN stage 1 patients
as non-aggressive PrCa and individuals with metastatic disease
(Mþ ) or nodal spread (Nþ ) as aggressive (395 NCCN1 vs 1391
Mþ /Nþ ), whereas to enhance the sample panel available for this
analysis we also compared patients with Gleason Stage (GS) p6
against those with GS X8 disease (9626 GS p6 vs 2776 GS X8).
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RESULTS
Using genotype data from the iCOGS study imputed to the 1000
genomes phase 3 reference panel we analysed 81 303 SNPs within a
20-kb flanking region of 179 genes with a core function in DNA-
damage repair (Supplementary Table 1). Rare and uncommon
variants represented a substantial proportion of the data set, with
29 503 variants of MAF p1%, 16 689 with MAF 1–5% and 35 111
with MAF 45% (Supplementary Figure 1a). Variants were
categorised as SNPs, insertions and deletions, annotated using
wANNOVAR (Wang et al, 2010; Chang and Wang, 2012), and
classified into five categories; coding, UTR, splice, intronic and
intergenic. Variants available for this analysis were predominantly
situated within non-coding (intronic or intergenic) regions, with
3943 variants annotated as coding, splice or UTR in total, whereas
most were single-base substitutions, with 3914 insertions and 5576
deletions, respectively. All of the insertion and deletion variants
were imputed, with the vast majority located within non-coding
regions (Supplementary Figure 1b–d, Supplementary Table 2). All
analyses were adjusted for study population and the first eight
principal components. For single-variant level analyses the
genome-wide significance threshold (Po5 10 8) was used to
determine significantly associated variants, whereas for gene and
pathway level analyses the significance threshold was defined
according to the Bonferroni correction (gene Po2.7 10 4,
pathway Po5.56 10 3).
Single-variant analysis for association of DNA-repair gene
variants with PrCa identified only the previously reported
association with RAD51B at Chr14q24 (rs371311594, P¼ 1.29
 10 10). Several other gene loci showed suggestive association
peaks; however, no other variants were within one order of
magnitude of genome-wide significance (Figure 1, Supplementary
Table 3).
We observed evidence for modest inflation within our association
data (l¼ 1.105); nonetheless, departure from the null was apparent
towards the extremity of the P-value distribution and this persisted to
a more modest extent even after the RAD51B region was excluded
(Supplementary Figure 2). We subsequently performed gene level
association tests, in an attempt to ascertain whether additional
putative PrCa-risk signals might be present among the genes within
which no individual variant achieved significance after adjustment
for multiple testing, arising through a cumulative effect of several low
MAF or low penetrance variants. We performed two gene-level
association tests using the SKAT; SKAT-C, which is optimised for
combined testing of rare and common variants and SKAT-O, which
attempts to maximise power for rare variant testing (Lee et al, 2012;
Ionita-Laza et al, 2013). Gene-level analysis identified a novel
significant association with the MSH5 gene using the SKAT-C test
(Chr6p21; P¼ 1.68 10 4) (Figure 2, Supplementary Table 4). We
used stepAIC and leave one out for SKAT to further interrogate the
MSH5 data for the individual variants that best explain the signal.
This test selected three variants at the MSH5 locus, rs61036903
(known as 6 : 31713892 within the reference panel) intronic within
the gene and two variants 10-kb downstream within an adjacent gene
VWA7, rs805825 and rs185333600. These were all among the
top-ranking variants in the single-SNP analysis (rs61036903:
MAF¼ 0.14, OR 0.92, P¼ 8.06 10 5; rs805825: MAF¼ 0.45, OR
0.94, P¼ 4.05 10 5; rs185333600: MAF¼ 0.003, OR 1.57,
P¼ 6.83 10 4).
We subsequently examined the iCOGS data set at the pathway
level under the SKAT test to supplement the gene-level analyses. We
again used the Bonferroni correction to define the significance
threshold (pathway Po5.56 10 3). No pathway achieved sig-
nificance at this threshold, with suggestive associations under the
SKAT-O test observed with the translesion synthesis pathway
(P¼ 6.18 10 3) and mismatch-repair pathway (P¼ 0.056).
Variants within the coding sequence of DNA-repair genes could
be more likely to influence PrCa risk than those in non-coding
regions. We therefore performed an additional SKAT test to assess
whether the coding DNA-repair gene variants available for this study,
when collapsed as a single entity, could stratify case and control
status. We observed a significant association when using the SKAT-C
test (P¼ 0.003), which suggests that variants that affect the coding
sequence of genes participating in DNA-repair processes contribute
to PrCa risk. We attempted to further elaborate upon this finding by
analysing coding variation within each pathway separately. Despite
relatively modest numbers of coding variants available within each
pathway, we continued to observe suggestive associations under the
SKAT-O test for the translesion synthesis pathway (P¼ 0.026) and
mismatch-repair pathway (P¼ 0.055), in addition to the HR/FA
pathway under the SKAT-C test (P¼ 0.011).
To complement the tests designed to identify potential PrCa
susceptibility variants and genes, we also performed case–case
analyses to investigate whether individual or cumulative germline
DNA-repair gene and pathway variants in the iCOGS imputed
data set correlated with phenotypic characteristics of more
aggressive PrCa. This analysis was limited by lack of complete
phenotypic data for all patients within the iCOGS sample set and
low numbers of samples within individual phenotypic subgroups;
therefore, we utilised two separate criteria to define aggressive and
non-aggressive disease. For a stringent comparison of non-
aggressive and aggressive PrCa, we analysed NCCN stage 1
patients against individuals with metastatic disease (Mþ ) or nodal
spread (Nþ ) (395 NCCN1 vs 1391 Mþ /Nþ ), whereas to maximise
the number of samples available we also compared patients with
GS p6 disease against those with GS X8 (9626 GS p6 vs 2776
GS X8). No significant associations with aggressive PrCa
were identified at either the variant or gene levels for either
of the phenotypic criteria tested. (Supplementary Figure 3,
Supplementary Table 5). When we examined PrCa aggressiveness
at the pathway level, we observed associations at Po0.05 for the
HR/FA pathway under both tests for the GS p6 vs GS X8
phenotype cohort (SKAT-C P¼ 0.011, SKAT-O P¼ 0.040).
This pathway was also the highest ranked for the NCCN1 vs
Mþ /Nþ phenotype cohort under the SKAT-C test (P¼ 0.052).
When these analyses were restricted to only coding variants, an
association at Po0.05 remained for the HR/FA pathway for the
NCCN1 vs Mþ /Nþ cohort and the SKAT-O test (P¼ 0.021).
These suggestive associations were not however significant after
adjustment for multiple testing (Supplementary Table 5).
DISCUSSION
DNA-repair genes have a crucial role in the correction of damage
to the genome of a cell and therefore their impairment can lead to
carcinogenesis. Although these detrimental genetic alterations
frequently originate within somatic cells during an individual’s
lifetime, a number of rare, hereditary mutations within specific
DNA-repair genes have been identified that confer substantially
increased risks to the individual of PrCa and other cancers. GWAS
have also previously identified common, low-penetrance variants
in close proximity to the DNA-repair genes RAD51B and RAD23B
that contribute to PrCa susceptibility (Xu et al, 2012; Eeles et al,
2013; Amin Al Olama et al, 2015). However, even relatively well-
powered genetic association studies may have been limited in their
ability to reliably interrogate variants with lower MAFs or
associations with modest effect sizes; therefore, additional-risk
variants that confer their functional effect though DNA-repair
genes may remain to be discovered. We have recently imputed
PrCa data from the iCOGS study to the 1000 Genomes phase 3
reference panel, thereby enhancing the capability to interrogate this
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data set for untyped variants within tagged regions. In particular, a
far greater number of lower MAF and insertion and deletion
variants were available for analysis, although these are predomi-
nantly situated in non-coding regions. Imputation performance of
lower MAF variants is improved by larger reference panel size and
ethnic diversity and higher marker density on the genotyping
array; however, rare variants still regularly remain challenging to
impute without an additional reference panel enriched for specific
low-frequency variants of known interest, and may also be more
sensitive to differences in the imputation approach employed
(Hoffmann and Witte, 2015). Our relatively large sample size
provided good power to detect associations with PrCa for rare
variants with greater effect sizes (e.g., for a variant at our 0.1%
MAF cutoff with OR 2.5, we had 78% power) as well as common,
low-penetrance variants (e.g., for a variant with OR 1.1 and a MAF
of 20%, power was 86%). We were however limited with respect to
the detection of variants with the combination of both modest
allele frequency and effect size.
We have examined all variants in the imputed iCOGS data set
situated within 20-kb of a panel of 179 DNA-repair genes for
association with PrCa or more aggressive phenotypic presentation.
No novel risk variants were identified in our single-SNP analysis,
with only the previously reported signal at RAD51B on Chr14q24
genome-wide significant (Figure 1, Supplementary Table 3).
Our analysis did not detect the previously reported signal at the
RAD23B locus on Chr9q31, which was originally identified in the
Chinese population and recently also confirmed in Europeans with
the most significantly associated variant rs1771718 and the signal
also an eQTL for RAD23B in normal prostate tissue in the TCGA
data set (Xu et al, 2012; Amin Al Olama et al, 2015). rs1771718 is
located B57 kb downstream of RAD23B, which is the closest
neighbouring gene but located in a distinct recombination block
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Figure 2. Case–control Manhattan Plots for the 179 DNA-repair genes analysed by SKAT. (A) A significant association was observed for theMSH5
gene using the SKAT-C test that examines the combined effect of common and rare variants. (B) No significant association was detected for any
gene under the SKAT-O test that primarily focuses on rare variant association testing.
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Figure 1. Single SNP case–control Manhattan Plot. In total, 81 303 SNPs from 179 DNA-repair genes were analysed for association with PrCa.
Only the previously reported association within the RAD51B gene was identified, with suggestive, non-significant association peaks observed at a
small number of other loci.
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from these risk variants. As no variant among the 509 within the
gene centric region that we interrogated in this study showed
substantial evidence for association (PX2.94 10 3), it appears
likely that risk at this locus is modulated through a nearby
regulatory element controlling expression of the gene as opposed to
intragenic causal functional variants (Supplementary Figure 4).
We conducted two gene-level analyses in an attempt to identify
whether there may be additional signals among the several loci that
demonstrated suggestive but non-significant association peaks
in our single-SNP analysis, but for which no individual variant
had achieved significance. SKAT-C tests for the combined effects of
common and rare variants, whereas SKAT-O adaptively combines
the burden test and SKAT test in an attempt to maximise power for
rare variant association testing (Lee et al, 2012; Ionita-Laza et al,
2013). We identified a significant PrCa-risk association after
adjustment for multiple testing at the MSH5 gene at Chr6p21 using
the SKAT-C test, implying that multiple common, or a combination
of common and rare variants within this gene may contribute to
PrCa risk. Although caution must be taken with respect to this
finding until replicated and deconstructed, this evidence implicates
MSH5 as a prospective PrCa susceptibility locus that warrants
additional follow-up. MSH5 had previously been reported as a
plausible candidate gene for the lung cancer-risk locus at Chr6p21.33,
for which the most strongly associated variant rs3117582 is intronic
in BAT3; however, is highly correlated to rs3131379 in intron 10 of
MSH5 (Wang et al, 2008; Kazma et al, 2012). A recent study
examining cancer pleiotropy among DNA-repair and DNA-damage
signalling pathway variants has also reported a highly significant
association with lung cancer for rs3115672, a synonymous variant
within MSH5, in addition to weaker associations with colon and
serous ovarian cancers (pleiotropic OR 1.18, 95% CI 1.12-1.24,
P¼ 2.53 10 8) (Scarbrough et al, 2016). This variant was however
non-significant for PrCa within their study of 14 160 PrCa cases and
12 724 controls (OR 0.96, P¼ 0.21). Within our larger study (of
which 2614 cases and 2679 controls overlapped with those of
Scarbrough et al), in the single-SNP analysis, rs3115672 remained
non-significant after adjustment for multiple testing (OR 0.94, 95%
CI 0.90–0.98, P¼ 5.69 10 3). However, a number of other variants
among the 312 within the MSH5 gene in our analysis were more
strongly associated, the top individual variant of which was
rs9281573 (OR 0.94, P¼ 4.01 10 5). StepAIC combined with
SKAT leave one out selected two common and one rare variant as
best explaining the SKAT-C association, all of which were among the
top variants in the single-SNP analysis. This implies that a
combination of common and rare variants could potentially
underpin this signal.
We annotated these three variants for evidence of functionality
using HaploReg v4.1 (Ward and Kellis, 2016); this annotation
included chromatin state data for cell lines derived from multiple
tissue types provided by the Roadmap Epigenomics Consortium
(Roadmap Epigenomics et al, 2015); however, no data for prostate
tissue were available. rs61036903, which is intronic to MSH5,
showed limited direct evidence for functionality itself. Both of the
variants situated around the MSH5 promoter region, within
VWA7, showed strong evidence for being located within enhancer
elements that are active across a wide range of tissue types.
In addition, expression data from the GTEx Consortium indicates
that rs805825 is an eQTL for a number of genes from the MHC
region (HLA-DRB1, HLA-DRB5, LY6G5C, DDAH2, LY6G6C,
HSPA1B and C4B) (GTEx Consortium, 2015). These genes are
clustered closely centromeric and telomeric of MSH5 and VWA7
within a gene dense locus; however, no eQTL with MSH5 or
VWA7 was observed for this variant.
Although the MSH5 gene is routinely classified as a member of
the MMR pathway along with all other homologues of MutS
(Wood et al, 2005; Ji et al, 2012; Scarbrough et al, 2016), functional
evidence to date provides limited support for a role in MMR for
MSH5 itself. Instead, this gene has been implicated primarily in the
processes of meiotic recombination, maintenance of chromosome
integrity and DNA double-strand break repair (Clark et al, 2013;
Wu et al, 2013). RNA-seq data from GTEx Analysis Release V6 for
2712 total samples across 51 normal human tissues (including 106
prostate tissue samples) demonstrates that MSH5 is expressed at
broadly similar levels across a wide range of tissue types, including
prostate (GTEx Consortium, 2015; accessed via. http://www.gtex-
portal.org/home/gene/MSH5). Data from TCGA further support
this expression profile across a range of normal tissues and also
indicates that MSH5 is consistently overexpressed for almost all
tumour types in comparison with their respective normal tissues.
For TCGA prostate tissue, a median RSEM (log2) value of 8.08 was
observed across 498 tumour samples compared with 6.85 from 52
normal samples (http://cancergenome.nih.gov/; accessed via.
http://firebrowse.org/viewGene.html?gene=msh5).
Taken together, these information demonstrate that although the
MSH5 gene represents a strong biological candidate for the PrCa-risk
association that we have observed, additional functional follow-up
studies will be required to dissect the precise functional variants,
genes, regulatory elements or processes that underpin this signal.
It is worth noting that the gene level analyses in this study did
not identify significant associations with any genes previously
implicated in PrCa susceptibility. This was irrespective of whether
the known risk mechanisms are believed to operate through
multiple common, low-penetrance variants (e.g., RAD51B; SKAT-
O P¼ 0.05, SKAT-C P¼ 2.76 10 3) or rare coding variants (e.g.,
BRCA2; SKAT-O P¼ 0.46, SKAT-C P¼ 0.15). In the case of
BRCA2 and other genes in which rare, moderate penetrance,
protein truncating PrCa susceptibility variants had previously been
identified, this is likely to reflect the fact that even using the latest
1000 Genomes reference panel, rare variants expected to confer
greater phenotypic consequences may remain absent from the
reference panel and consequently unimputable. This is consistent
with the poor representation of coding insertion and deletion
variants within our data set and would have rendered us
underpowered to detect the effects of this class of variation in
our analysis. Our observations do however imply that any
additional contribution from common, lower penetrance variation
at these genes may be minimal. This includes the rs11571833
nonsense polymorphism in the terminal exon of BRCA2, which is a
reported lung cancer susceptibility variant, but was not associated
with PrCa in this study (OR 1.03, 95% CI 0.89–1.19, P¼ 0.74)
(Wang et al, 2014). It is perhaps more surprising that RAD51B did
not achieve significance under the SKAT-C test, which considers
the potential contribution towards association of both common
and rare variants within a region, given that three independent
associations have previously been identified at this locus (Amin Al
Olama et al, 2015). However, a suggestive association was observed
under this test, which may be an indication that the cumulative
effect size of the independent low-penetrance-risk variants within
this region were insufficient to be conclusively disambiguated
through this methodology.
Our pathway-level analysis identified suggestive but non-
significant associations for two pathways under the SKAT-O test;
translesion synthesis and mismatch repair. Although this study did
not therefore provide sufficient evidence to implicate genes within
these pathways in PrCa susceptibility, given the inherently
conservative nature of the Bonferroni correction with respect to
type II error and the relatively low proportion of coding variants
within our data set, these observations may still justify further
evaluation. In particular, as these suggestive associations were
observed under the SKAT-O test that maximises power for rare
variant association analyses and were not abrogated when the
analyses were restricted only to coding variants, if substantiated,
these nascent observations could be underpinned by direct effects
of rare variants on the protein structure and function.
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Consequently, sequencing studies designed to comprehensively
analyse the entire coding sequence of genes within the translesion
synthesis and mismatch repair pathways could potentially yield
further insight towards the mechanisms of susceptibility to
developing PrCa. It is also worth noting that somatic mutations
in translesion synthesis pathway genes, in particular the POLK
gene, have been observed in prostate tumours previously
(Makridakis and Reichardt, 2012; Yadav et al, 2015), whereas a
rare germline nonsynonymous variant in the POLI gene has also
been reported to predispose towards the occurrence of the
TMPRSS2-ERG fusion in PrCa patients (Luedeke et al, 2009).
Increasing evidence suggests that moderate-penetrance germline
mutations within DNA-repair genes also correlate with a more
aggressive phenotypic presentation of PrCa and poorer prognosis
(Castro et al, 2013; Cybulski et al, 2013; Leongamornlert et al,
2014; Robinson et al, 2015). This could in turn signify that DNA-
repair gene variants might exist that do not confer greater risk of
developing PrCa per se, yet do modify the likelihood of developing
more aggressive disease in individuals that develop PrCa owing to
other risk factors or exposures. We therefore also performed case–
case analyses to further explore this hypothesis using two distinct
phenotypic criteria. No significant or suggestive associations with
aggressive disease were identified at the individual variant or gene
levels under either definition; however, suggestive non-significant
associations with the HR/FA pathway were observed. These analyses
were, however, limited by relatively low sample numbers within each
comparison group, which would have reduced our power to detect
associations, particularly for rare and uncommon variants. We
cannot therefore exclude the existence of additional DNA-repair gene
variants that promote increased PrCa aggressiveness rather than risk
of the disease itself; however, our data would suggest that any that
exist are more likely to be rare than common.
Overall, this study represents the most comprehensive interroga-
tion of the role of DNA-repair gene variants in PrCa susceptibility
that we are aware of to date. We confirmed the presence of
low-penetrance susceptibility loci situated at the RAD51B locus and
found evidence to implicate a novel gene, MSH5, in PrCa
susceptibility. We also share preliminary observations that rare
germline variation in genes within the translesion synthesis pathway,
in particular variants within the coding sequence, could be worthy of
further investigation as candidates for PrCa risk.
The main limitations of our study relate to the challenges in
imputing rare, potentially pathogenic variants to array genotype data
from population-based reference panels and in performing associa-
tion tests on low-frequency variants in a large multi-population study
while controlling for population stratification. Therefore, additional
sequencing studies would still be warranted to further explore the
contribution of rare DNA-repair gene variants to PrCa risk. In
addition, incomplete availability of phenotypic data and the fact that
the iCOGS study did not specifically select individuals with low- or
high-grade disease may have reduced our ability to examine any
potential influence of these variants on PrCa aggressiveness. Future
studies, whether array or sequencing based, that specifically select
patients from these cohorts for inclusion would facilitate investiga-
tion of this aspect; which might in turn help to enhance stratification
of patients that require altered clinical management pathways.
CONFLICT OF INTEREST
The authors declare no conflict of interest.
REFERENCES
Al Olama AA, Kote-Jarai Z, Berndt SI, Conti DV, Schumacher F, Han Y,
Benlloch S, Hazelett DJ, Wang Z, Saunders E, Leongamornlert D,
Lindstrom S, Jugurnauth-Little S, Dadaev T, Tymrakiewicz M, Stram DO,
Rand K, Wan P, Stram A, Sheng X, Pooler LC, Park K, Xia L, Tyrer J,
Kolonel LN, Le Marchand L, Hoover RN, Machiela MJ, Yeager M,
Burdette L, Chung CC, Hutchinson A, Yu K, Goh C, Ahmed M,
Govindasami K, Guy M, Tammela TL, Auvinen A, Wahlfors T,
Schleutker J, Visakorpi T, Leinonen KA, Xu J, Aly M, Donovan J,
Travis RC, Key TJ, Siddiq A, Canzian F, Khaw KT, Takahashi A, Kubo M,
Pharoah P, Pashayan N, Weischer M, Nordestgaard BG, Nielsen SF,
Klarskov P, Roder MA, Iversen P, Thibodeau SN, McDonnell SK,
Schaid DJ, Stanford JL, Kolb S, Holt S, Knudsen B, Coll AH, Gapstur SM,
Diver WR, Stevens VL, Maier C, Luedeke M, Herkommer K, Rinckleb AE,
Strom SS, Pettaway C, Yeboah ED, Tettey Y, Biritwum RB, Adjei AA,
Tay E, Truelove A, Niwa S, Chokkalingam AP, Cannon-Albright L,
Cybulski C, Wokolorczyk D, Kluzniak W, Park J, Sellers T, Lin HY,
Isaacs WB, Partin AW, Brenner H, Dieffenbach AK, Stegmaier C, Chen C,
Giovannucci EL, Ma J, Stampfer M, Penney KL, Mucci L, John EM,
Ingles SA, Kittles RA, Murphy AB, Pandha H, Michael A, Kierzek AM,
Blot W, Signorello LB, Zheng W, Albanes D, Virtamo J, Weinstein S,
Nemesure B, Carpten J, Leske C, Wu SY, Hennis A, Kibel AS, Rybicki BA,
Neslund-Dudas C, Hsing AW, Chu L, Goodman PJ, Klein EA, Zheng SL,
Batra J, Clements J, Spurdle A, Teixeira MR, Paulo P, Maia S, Slavov C,
Kaneva R, Mitev V, Witte JS, Casey G, Gillanders EM, Seminara D,
Riboli E, Hamdy FC, Coetzee GA, Li Q, Freedman ML, Hunter DJ,
Muir K, Gronberg H, Neal DE, Southey M, Giles GG, Severi G.
Breast, Prostate Cancer Cohort C, Consortium P, Consortium C,
Consortium G-OECook MB, Nakagawa H, Wiklund F, Kraft P,
Chanock SJ, Henderson BE, Easton DF, Eeles RA, Haiman CA (2014)
A meta-analysis of 87 040 individuals identifies 23 new susceptibility loci
for prostate cancer. Nat Genet 46(10): 1103–1109.
Amin Al Olama A, Dadaev T, Hazelett DJ, Li Q, Leongamornlert D,
Saunders EJ, Stephens S, Cieza-Borrella C, Whitmore I, Benlloch Garcia S,
Giles GG, Southey MC, Fitzgerald L, Gronberg H, Wiklund F, Aly M,
Henderson BE, Schumacher F, Haiman CA, Schleutker J, Wahlfors T,
Tammela TL, Nordestgaard BG, Key TJ, Travis RC, Neal DE, Donovan JL,
Hamdy FC, Pharoah P, Pashayan N, Khaw KT, Stanford JL,
Thibodeau SN, McDonnell SK, Schaid DJ, Maier C, Vogel W, Luedeke M,
Herkommer K, Kibel AS, Cybulski C, Wokolorczyk D, Kluzniak W,
Cannon-Albright L, Brenner H, Butterbach K, Arndt V, Park JY, Sellers T,
Lin HY, Slavov C, Kaneva R, Mitev V, Batra J, Clements JA, Spurdle A,
Teixeira MR, Paulo P, Maia S, Pandha H, Michael A, Kierzek A,
Govindasami K, Guy M, Lophatonanon A, Muir K, Vinuela A, Brown AA.
Consortium P, Initiative C-CG-E, Australian Prostate Cancer B,
Collaborators UKGPCS, Collaborators UKPSFreedman M, Conti DV,
Easton D, Coetzee GA, Eeles RA, Kote-Jarai Z (2015) Multiple novel
prostate cancer susceptibility signals identified by fine-mapping
of known risk loci among Europeans. Hum Mol Genet 24(19):
5589–5602.
Attard G, Parker C, Eeles RA, Schroder F, Tomlins SA, Tannock I, Drake CG,
de Bono JS (2015) Prostate cancer. Lancet 387(10013): 70–82.
Cancer Research UK (2014) Cancer Statistics Report: Cancer Incidence and
Mortality in the UK, September 2014.
Castro E, Goh C, Olmos D, Saunders E, Leongamornlert D, Tymrakiewicz M,
Mahmud N, Dadaev T, Govindasami K, Guy M, Sawyer E, Wilkinson R,
Ardern-Jones A, Ellis S, Frost D, Peock S, Evans DG, Tischkowitz M,
Cole T, Davidson R, Eccles D, Brewer C, Douglas F, Porteous ME,
Donaldson A, Dorkins H, Izatt L, Cook J, Hodgson S, Kennedy MJ,
Side LE, Eason J, Murray A, Antoniou AC, Easton DF, Kote-Jarai Z,
Eeles R (2013) Germline BRCA mutations are associated with higher risk
of nodal involvement, distant metastasis, and poor survival outcomes in
prostate cancer. J Clin Oncol 31(14): 1748–1757.
Chang X, Wang K (2012) wANNOVAR: annotating genetic variants for
personal genomes via the web. J Med Genet 49(7): 433–436.
Clark N, Wu X, Her C (2013) MutS homologues hMSH4 and hMSH5: genetic
variations, functions, and implications in human diseases. Curr Genomics
14(2): 81–90.
Cybulski C, Wokolorczyk D, Kluzniak W, Jakubowska A, Gorski B,
Gronwald J, Huzarski T, Kashyap A, Byrski T, Debniak T, Golab A,
Gliniewicz B, Sikorski A, Switala J, Borkowski T, Borkowski A, Antczak A,
Wojnar L, Przybyla J, Sosnowski M, Malkiewicz B, Zdrojowy R,
Sikorska-Radek P, Matych J, Wilkosz J, Rozanski W, Kis J, Bar K,
Bryniarski P, Paradysz A, Jersak K, Niemirowicz J, Slupski P, Jarzemski P,
Skrzypczyk M, Dobruch J, Domagala P, Narod SA, Lubinski J.
Polish Hereditary Prostate Cancer C (2013) An inherited NBN mutation
BRITISH JOURNAL OF CANCER DNA repair gene variation and prostate cancer risk
950 www.bjcancer.com |DOI:10.1038/bjc.2016.50
is associated with poor prognosis prostate cancer. Br J Cancer 108(2):
461–468.
Delaneau O, Zagury JF, Marchini J (2013) Improved whole-chromosome
phasing for disease and population genetic studies. Nat Methods 10(1):
5–6.
Dong X, Wang L, Taniguchi K, Wang X, Cunningham JM, McDonnell SK,
Qian C, Marks AF, Slager SL, Peterson BJ, Smith DI, Cheville JC,
Blute ML, Jacobsen SJ, Schaid DJ, Tindall DJ, Thibodeau SN, Liu W (2003)
Mutations in CHEK2 associated with prostate cancer risk. Am J Hum
Genet 72(2): 270–280.
Eeles R, Goh C, Castro E, Bancroft E, Guy M, Al Olama AA, Easton D,
Kote-Jarai Z (2014) The genetic epidemiology of prostate cancer and its
clinical implications. Nat Rev Urol 11(1): 18–31.
Eeles RA, Olama AA, Benlloch S, Saunders EJ, Leongamornlert DA,
Tymrakiewicz M, Ghoussaini M, Luccarini C, Dennis J,
Jugurnauth-Little S, Dadaev T, Neal DE, Hamdy FC, Donovan JL, Muir K,
Giles GG, Severi G, Wiklund F, Gronberg H, Haiman CA, Schumacher F,
Henderson BE, Le Marchand L, Lindstrom S, Kraft P, Hunter DJ,
Gapstur S, Chanock SJ, Berndt SI, Albanes D, Andriole G, Schleutker J,
Weischer M, Canzian F, Riboli E, Key TJ, Travis RC, Campa D,
Ingles SA, John EM, Hayes RB, Pharoah PD, Pashayan N, Khaw KT,
Stanford JL, Ostrander EA, Signorello LB, Thibodeau SN, Schaid D,
Maier C, Vogel W, Kibel AS, Cybulski C, Lubinski J, Cannon-Albright L,
Brenner H, Park JY, Kaneva R, Batra J, Spurdle AB, Clements JA,
Teixeira MR, Dicks E, Lee A, Dunning AM, Baynes C, Conroy D,
Maranian MJ, Ahmed S, Govindasami K, Guy M, Wilkinson RA,
Sawyer EJ, Morgan A, Dearnaley DP, Horwich A, Huddart RA, Khoo VS,
Parker CC, Van As NJ, Woodhouse CJ, Thompson A, Dudderidge T,
Ogden C, Cooper CS, Lophatananon A, Cox A, Southey MC, Hopper JL,
English DR, Aly M, Adolfsson J, Xu J, Zheng SL, Yeager M, Kaaks R,
Diver WR, Gaudet MM, Stern MC, Corral R, Joshi AD, Shahabi A,
Wahlfors T, Tammela TL, Auvinen A, Virtamo J, Klarskov P,
Nordestgaard BG, Roder MA, Nielsen SF, Bojesen SE, Siddiq A,
Fitzgerald LM, Kolb S, Kwon EM, Karyadi DM, Blot WJ, Zheng W, Cai Q,
McDonnell SK, Rinckleb AE, Drake B, Colditz G, Wokolorczyk D,
Stephenson RA, Teerlink C, Muller H, Rothenbacher D, Sellers TA,
Lin HY, Slavov C, Mitev V, Lose F, Srinivasan S, Maia S, Paulo P,
Lange E, Cooney KA, Antoniou AC, Vincent D, Bacot F, Tessier DC.
Initiative CO-CRUG-E, Australian Prostate Cancer BOncology
UKGPCSCBAoUSSo, Collaborators UKPS, Consortium PKote-Jarai Z,
Easton DF (2013) Identification of 23 new prostate cancer susceptibility
loci using the iCOGS custom genotyping array. Nat Genet 45(4):
385–391e1–2.
GTEx Consortium (2015) Human genomics. the genotype-tissue expression
(GTEx) pilot analysis: multitissue gene regulation in humans. Science
348(6235): 648–460.
Hjelmborg JB, Scheike T, Holst K, Skytthe A, Penney KL, Graff RE, Pukkala E,
Christensen K, Adami HO, Holm NV, Nuttall E, Hansen S, Hartman M,
Czene K, Harris JR, Kaprio J, Mucci LA (2014) The heritability of prostate
cancer in the Nordic Twin Study of Cancer. Cancer Epidemiol Biomarkers
Prev 23(11): 2303–2310.
Hoffmann TJ, Witte JS (2015) Strategies for imputing and analyzing rare
variants in association studies. Trends Genet 31(10): 556–563.
Howie BN, Donnelly P, Marchini J (2009) A flexible and accurate genotype
imputation method for the next generation of genome-wide association
studies. PLoS Genet 5(6): e1000529.
Ilic D, Neuberger MM, Djulbegovic M, Dahm P (2013) Screening for prostate
cancer. Cochrane Database Syst Rev 1: CD004720.
Ionita-Laza I, Lee S, Makarov V, Buxbaum JD, Lin X (2013) Sequence
kernel association tests for the combined effect of rare and common
variants. Am J Hum Genet 92(6): 841–853.
Ji G, Long Y, Zhou Y, Huang C, Gu A, Wang X (2012) Common variants in
mismatch repair genes associated with increased risk of sperm DNA
damage and male infertility. BMC Med 10: 49.
Kang J, D’Andrea AD, Kozono D (2012) A DNA repair pathway-focused
score for prediction of outcomes in ovarian cancer treated with platinum-
based chemotherapy. J Natl Cancer Inst 104(9): 670–681.
Kazma R, Babron MC, Gaborieau V, Genin E, Brennan P, Hung RJ,
McLaughlin JR, Krokan HE, Elvestad MB, Skorpen F, Anderssen E,
Vooder T, Valk K, Metspalu A, Field JK, Lathrop M, Sarasin A,
Benhamou S, consortium I (2012) Lung cancer and DNA repair genes:
multilevel association analysis from the International Lung Cancer
Consortium. Carcinogenesis 33(5): 1059–1064.
Kote-Jarai Z, Jugurnauth S, Mulholland S, Leongamornlert DA, Guy M,
Edwards S, Tymrakiewitcz M, O’Brien L, Hall A, Wilkinson R,
Al Olama AA, Morrison J, Muir K, Neal D, Donovan J, Hamdy F,
Easton DF, Eeles R. Collaborators U, British Association of Urological
Surgeons’ Section of O (2009) A recurrent truncating germline mutation
in the BRIP1/FANCJ gene and susceptibility to prostate cancer.
Br J Cancer 100(2): 426–430.
Kote-Jarai Z, Leongamornlert D, Saunders E, Tymrakiewicz M, Castro E,
Mahmud N, Guy M, Edwards S, O’Brien L, Sawyer E, Hall A,
Wilkinson R, Dadaev T, Goh C, Easton D. Collaborators U, Goldgar D,
Eeles R (2011) BRCA2 is a moderate penetrance gene contributing to
young-onset prostate cancer: implications for genetic testing in prostate
cancer patients. Br J Cancer 105(8): 1230–1234.
Lee S, Emond MJ, Bamshad MJ, Barnes KC, Rieder MJ, Nickerson DA.
Team NGESP-ELPChristiani DC, Wurfel MM, Lin X (2012) Optimal
unified approach for rare-variant association testing with application to
small-sample case-control whole-exome sequencing studies. Am J Hum
Genet 91(2): 224–237.
Leongamornlert D, Mahmud N, Tymrakiewicz M, Saunders E, Dadaev T,
Castro E, Goh C, Govindasami K, Guy M, O’Brien L, Sawyer E, Hall A,
Wilkinson R, Easton D. Collaborators UGoldgar D, Eeles R, Kote-Jarai Z
(2012) Germline BRCA1 mutations increase prostate cancer risk.
Br J Cancer 106(10): 1697–1701.
Leongamornlert D, Saunders E, Dadaev T, Tymrakiewicz M, Goh C,
Jugurnauth-Little S, Kozarewa I, Fenwick K, Assiotis I, Barrowdale D,
Govindasami K, Guy M, Sawyer E, Wilkinson R. Collaborators U
Antoniou AC, Eeles R, Kote-Jarai Z (2014) Frequent germline deleterious
mutations in DNA repair genes in familial prostate cancer cases are
associated with advanced disease. Br J Cancer 110(6):
1663–1672.
Luedeke M, Linnert CM, Hofer MD, Surowy HM, Rinckleb AE, Hoegel J,
Kuefer R, Rubin MA, Vogel W, Maier C (2009) Predisposition for
TMPRSS2-ERG fusion in prostate cancer by variants in DNA repair genes.
Cancer Epidemiol Biomarkers Prev 18(11): 3030–3035.
Makridakis NM, Reichardt JK (2012) Translesion DNA polymerases and
cancer. Front Genet 3: 174.
Quaresma M, Coleman MP, Rachet B (2015) 40-year trends in an index of
survival for all cancers combined and survival adjusted for age and sex for
each cancer in England and Wales, 1971-2011: a population-based study.
Lancet 385(9974): 1206–12018.
Roadmap Epigenomics C, Kundaje A, Meuleman W, Ernst J, Bilenky M,
Yen A, Heravi-Moussavi A, Kheradpour P, Zhang Z, Wang J, Ziller MJ,
Amin V, Whitaker JW, Schultz MD, Ward LD, Sarkar A, Quon G,
Sandstrom RS, Eaton ML, Wu YC, Pfenning AR, Wang X, Claussnitzer M,
Liu Y, Coarfa C, Harris RA, Shoresh N, Epstein CB, Gjoneska E, Leung D,
Xie W, Hawkins RD, Lister R, Hong C, Gascard P, Mungall AJ, Moore R,
Chuah E, Tam A, Canfield TK, Hansen RS, Kaul R, Sabo PJ, Bansal MS,
Carles A, Dixon JR, Farh KH, Feizi S, Karlic R, Kim AR, Kulkarni A, Li D,
Lowdon R, Elliott G, Mercer TR, Neph SJ, Onuchic V, Polak P,
Rajagopal N, Ray P, Sallari RC, Siebenthall KT, Sinnott-Armstrong NA,
Stevens M, Thurman RE, Wu J, Zhang B, Zhou X, Beaudet AE, Boyer LA,
De Jager PL, Farnham PJ, Fisher SJ, Haussler D, Jones SJ, Li W,
Marra MA, McManus MT, Sunyaev S, Thomson JA, Tlsty TD, Tsai LH,
Wang W, Waterland RA, Zhang MQ, Chadwick LH, Bernstein BE,
Costello JF, Ecker JR, Hirst M, Meissner A, Milosavljevic A, Ren B,
Stamatoyannopoulos JA, Wang T, Kellis M (2015) Integrative analysis
of 111 reference human epigenomes. Nature 518(7539): 317–330.
Robinson D, Van Allen EM, Wu YM, Schultz N, Lonigro RJ, Mosquera JM,
Montgomery B, Taplin ME, Pritchard CC, Attard G, Beltran H, Abida W,
Bradley RK, Vinson J, Cao X, Vats P, Kunju LP, Hussain M, Feng FY,
Tomlins SA, Cooney KA, Smith DC, Brennan C, Siddiqui J, Mehra R,
Chen Y, Rathkopf DE, Morris MJ, Solomon SB, Durack JC, Reuter VE,
Gopalan A, Gao J, Loda M, Lis RT, Bowden M, Balk SP, Gaviola G,
Sougnez C, Gupta M, Yu EY, Mostaghel EA, Cheng HH, Mulcahy H, True
LD, Plymate SR, Dvinge H, Ferraldeschi R, Flohr P, Miranda S,
Zafeiriou Z, Tunariu N, Mateo J, Perez-Lopez R, Demichelis F,
Robinson BD, Schiffman M, Nanus DM, Tagawa ST, Sigaras A, Eng KW,
Elemento O, Sboner A, Heath EI, Scher HI, Pienta KJ, Kantoff P,
de Bono JS, Rubin MA, Nelson PS, Garraway LA, Sawyers CL,
Chinnaiyan AM (2015) Integrative clinical genomics of advanced
prostate cancer. Cell 161(5): 1215–1228.
Scarbrough PM, Weber RP, Iversen ES, Brhane Y, Amos CI, Kraft P, Hung RJ,
Sellers TA, Witte JS, Pharoah P, Henderson BE, Gruber SB, Hunter DJ,
DNA repair gene variation and prostate cancer risk BRITISH JOURNAL OF CANCER
www.bjcancer.com |DOI:10.1038/bjc.2016.50 951
Garber JE, Joshi AD, McDonnell K, Easton DF, Eeles R, Kote-Jarai Z,
Muir K, Doherty JA, Schildkraut JM (2016) A cross-cancer genetic
association analysis of the dna repair and dna damage signaling pathways
for lung, ovary, prostate, breast, and colorectal cancer. Cancer Epidemiol
Biomarkers Prev 25(1): 193–200.
Wang K, Li M, Hakonarson H (2010) ANNOVAR: functional annotation of
genetic variants from high-throughput sequencing data. Nucleic Acids Res
38(16): e164.
Wang Y, Broderick P, Webb E, Wu X, Vijayakrishnan J, Matakidou A,
Qureshi M, Dong Q, Gu X, Chen WV, Spitz MR, Eisen T, Amos CI,
Houlston RS (2008) Common 5p15.33 and 6p21.33 variants influence
lung cancer risk. Nat Genet 40(12): 1407–1409.
Wang Y, McKay JD, Rafnar T, Wang Z, Timofeeva MN, Broderick P,
Zong X, Laplana M, Wei Y, Han Y, Lloyd A, Delahaye-Sourdeix M,
Chubb D, Gaborieau V, Wheeler W, Chatterjee N, Thorleifsson G,
Sulem P, Liu G, Kaaks R, Henrion M, Kinnersley B, Vallee M,
LeCalvez-Kelm F, Stevens VL, Gapstur SM, Chen WV, Zaridze D,
Szeszenia-Dabrowska N, Lissowska J, Rudnai P, Fabianova E, Mates D,
Bencko V, Foretova L, Janout V, Krokan HE, Gabrielsen ME, Skorpen F,
Vatten L, Njolstad I, Chen C, Goodman G, Benhamou S, Vooder T,
Valk K, Nelis M, Metspalu A, Lener M, Lubinski J, Johansson M,
Vineis P, Agudo A, Clavel-Chapelon F, Bueno-de-Mesquita HB,
Trichopoulos D, Khaw KT, Johansson M, Weiderpass E, Tjonneland A,
Riboli E, Lathrop M, Scelo G, Albanes D, Caporaso NE, Ye Y, Gu J,
Wu X, Spitz MR, Dienemann H, Rosenberger A, Su L, Matakidou A,
Eisen T, Stefansson K, Risch A, Chanock SJ, Christiani DC, Hung RJ,
Brennan P, Landi MT, Houlston RS, Amos CI (2014) Rare variants of
large effect in BRCA2 and CHEK2 affect risk of lung cancer. Nat Genet
46(7): 736–741.
Ward LD, Kellis M (2016) HaploReg v4: systematic mining of putative causal
variants, cell types, regulators and target genes for human complex traits
and disease. Nucleic Acids Res 44(D1): D877–D881.
Wood RD, Mitchell M, Lindahl T (2005) Human DNA repair genes, 2005.
Mutat Res 577(1-2): 275–283.
Wu MC, Lee S, Cai T, Li Y, Boehnke M, Lin X (2011) Rare-variant association
testing for sequencing data with the sequence kernel association test.
Am J Hum Genet 89(1): 82–93.
Wu X, Xu Y, Feng K, Tompkins JD, Her C (2013) MutS homologue hMSH5:
recombinational DSB repair and non-synonymous polymorphic variants.
PLoS One 8(9): e73284.
Xu J, Mo Z, Ye D, Wang M, Liu F, Jin G, Xu C, Wang X, Shao Q, Chen Z,
Tao Z, Qi J, Zhou F, Wang Z, Fu Y, He D, Wei Q, Guo J, Wu D, Gao X,
Yuan J, Wang G, Xu Y, Wang G, Yao H, Dong P, Jiao Y, Shen M, Yang J,
Ou-Yang J, Jiang H, Zhu Y, Ren S, Zhang Z, Yin C, Gao X, Dai B, Hu Z,
Yang Y, Wu Q, Chen H, Peng P, Zheng Y, Zheng X, Xiang Y, Long J,
Gong J, Na R, Lin X, Yu H, Wang Z, Tao S, Feng J, Sun J, Liu W, Hsing A,
Rao J, Ding Q, Wiklund F, Gronberg H, Shu XO, Zheng W, Shen H, Jin L,
Shi R, Lu D, Zhang X, Sun J, Zheng SL, Sun Y (2012) Genome-wide
association study in Chinese men identifies two new prostate
cancer risk loci at 9q31.2 and 19q13.4. Nat Genet 44(11): 1231–1235.
Yadav S, Mukhopadhyay S, Anbalagan M, Makridakis N (2015)
Somatic mutations in catalytic core of POLK reported in prostate
cancer alter translesion DNA synthesis. Hum Mutat 36(9): 873–880.
This work is licensed under the Creative Commons
Attribution 4.0 International License. To view a
copy of this license, visit http://creativecommons.org/licenses/by/4.0/
Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)
1The Institute of Cancer Research & Royal Marsden NHS Foundation Trust, 123 Old Brompton Rd, London SW7 3RP, UK;
2Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Strangeways
Laboratory, Worts Causeway, Cambridge CB1 8RN, UK; 3Cancer Epidemiology Centre, The Cancer Council Victoria, 1 Rathdowne
Street, Carlton Victoria, Australia; 4Centre for Molecular, Environmental, Genetic and Analytic Epidemiology, The University of
Melbourne 3053, Victoria, Australia; 5Department of Medical Epidemiology and Biostatistics, Karolinska Institute, Stockholm
17177, Sweden; 6Department of Preventive Medicine, Keck School of Medicine, University of Southern California & Norris
Comprehensive Cancer Center, Los Angeles, CA 90089, USA; 7Department of Medical Biochemistry and Genetics, University of
Turku, Turku, Finland; 8Institute of Biomedical Technology and BioMediTech, University of Tampere and FimLab Laboratories,
Tampere 33520, Finland; 9Department of Clinical Biochemistry, Herlev and Gentofte Hospital, Copenhagen University Hospital,
Herlev Ringvej 75 DK-2730, Herlev, Denmark; 10Cancer Epidemiology Unit, Nuffield Department of Population Health, University
of Oxford, Oxford OX3 7LF, UK; 11Surgical Oncology (Uro-Oncology: S4), University of Cambridge, Addenbrooke’s Hospital,
Hills Road, Cambridge & Cancer Research UK Cambridge Research Institute, Li Ka Shing Centre, Cambridge CB2 2QQ,
UK; 12University College London, Department of Applied Health Research, 1-19 Torrington Place, London WC1E 7HB, UK;
13Cambridge Institute of Public Health, University of Cambridge, Forvie Site, Robinson Way, Cambridge CB2 0SR, UK;
14Department of Epidemiology, School of Public Health, University of Washington & Division of Public Health Sciences,
Fred Hutchinson Cancer Research Center, Seattle, WA, USA; 15International Epidemiology Institute, 1455 Research Blvd., Suite
550, Rockville MD 20850, USA; 16Mayo Clinic, Rochester, MN 55905, USA; 17Institute of Human Genetics, University Hospital Ulm,
Ulm 89075, Germany; 18Division of Urologic Surgery, Brigham and Women’s Hospital, Dana-Farber Cancer Institute, 45 Francis
Street- ASB II-3 Boston, MA, 02245, USA; 19International Hereditary Cancer Center, Department of Genetics and Pathology,
Pomeranian Medical University, Szczecin 70-115, Poland; 20Division of Genetic Epidemiology, Department of Medicine, University of
Utah School of Medicine & George E. Wahlen Department of Veterans Affairs Medical Center, Salt Lake City, UT 84132, USA;
21Division of Clinical Epidemiology and Aging Research, German Cancer Research Center (DKFZ), Heidelberg & Division of
Preventive Oncology, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg &
German Cancer Consortium (DKTK), German Cancer Research Center (DKFZ), Heidelberg, Germany; 22Department of Cancer
Epidemiology, H. Lee Moffitt Cancer Center, 12902 Magnolia Drive, Tampa, FL 33612, USA; 23Molecular Medicine Center and
Department of Medical Chemistry and Biochemistry, Medical University - Sofia, 2 Zdrave Street, Sofia 1431, Bulgaria; 24Australian
Prostate Cancer Research Centre-Qld, Institute of Health and Biomedical Innovation & School of Biomedical Science, Queensland
University of Technology, Brisbane 4102, Australia; 25Biomedical Sciences Institute (ICBAS), Porto University, Porto, Portugal;
26Department of Genetics, Portuguese Oncology Institute, Porto, Portugal 4200-072, Portugal; 27The University of Surrey,
Guildford, Surrey GU2 7XH, UK and 28Warwick Medical School, University of Warwick, Coventry CV4 7AL, UK
BRITISH JOURNAL OF CANCER DNA repair gene variation and prostate cancer risk
952 www.bjcancer.com |DOI:10.1038/bjc.2016.50
